Neisserial antigens

Details Neisserial antigens Neisserial antigens

2005-07-05

2005-07-05

Marschel, Ardin H. (Department: 1631)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C435S006120, C435S320100, C435S325000, C435S252300, C536S024100

Reexamination Certificate

active

06914131

ABSTRACT:
The invention provides proteins fromNeisseria meningitidis(strains A & B) and fromNeisseria gonorrhoeae, including amino acid sequences, the corresponding nucleotide sequences, expression data, and serological data. The proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics.

REFERENCES:
patent: 5288641 (1994-02-01), Roizman
patent: 5422120 (1995-06-01), Kim
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5591624 (1997-01-01), Barber et al.
patent: 5763188 (1998-06-01), Ohno et al.
patent: 6127180 (2000-10-01), Narva et al.
patent: 0 176 170 (1986-04-01), None
patent: 0 334 301 (1989-09-01), None
patent: 0 345 242 (1989-12-01), None
patent: 0 415 731 (1991-03-01), None
patent: 2 200 651 (1988-08-01), None
patent: WO 90/11092 (1990-10-01), None
patent: WO 92/05266 (1992-04-01), None
patent: WO 93/06223 (1993-04-01), None
patent: WO 93/07282 (1993-04-01), None
patent: WO 93/07283 (1993-04-01), None
patent: WO 93/14778 (1993-08-01), None
patent: WO 95/13796 (1995-05-01), None
patent: WO 95/30763 (1995-11-01), None
patent: WO 96/29412 (1996-09-01), None
patent: WO 98/20734 (1998-05-01), None
Sayers, J.R., Database GenEmbl, Acc. # AJ001740, May 21, 1998. See sequence alignments for SEQ ID NOs 653, 649, 651.
Meyer et al. Database GenEmbl, Acc. # A61829, Mar. 9, 1998. See sequence alignments for SEQ ID NOs 465, 463.
Barcak et al. Database GenEmbl, Acc. # HIU20229, Feb. 9, 1995. See sequence alignments for SEQ ID NOs 131, 127, and 125.
Paruchuri et al., Proc. Natl. Acad. Sci. USA, Vol. 87, pp. 333-337, Jan. 1990.
Szoka, et al., “Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation,”Proc. Natl. Acad. Sci. USA, 1978,75, 4194-4198.
Zollinger, “New and improved vaccines against meningococcal disease,”New Generation Vaccines, 2ndedition, Levine, et al. (eds.), Marcel Dekker, New York, 1997, 469-488.
Kohler, et al., “Continuous cultures of fused cells secreting antibody of predefined specificity,”Nature, 1975,256, 495-496.
Lieberman et al., “Safety and Immunogenicity of a Serogroups A/CNeisseria meningitidisOligosaccharide-Protein Conjugate Vaccine in Young Children,”JAMA, 1996,275(19), 1499-1503.
Morbidity and Mortality weekly report, “Control and prevention of meningococcal disease: recommendations of the advisory commitee on immunization practices (ACIP),” 1997,vol. 46, No. RR-5.
Poolman, J.T., “Development of a meningococcal vaccine,”Infect. Agents Dis., 1992,4, 13-28.
Quakyi, et al., “Development of a malaria T-cell vaccine for blood stage immunity,”Scand. J. Immunol., 1992,Suppl. 11, 9-16.
Roberts, et al., “Prediction of HIV peptide epitopes by a novel algorithm,”AIDS Res. Hum. Retrovir., 1996,12, 593-610.
Robinson, et al., “DNA vaccines,”Seminars in Immunology, 1997,9,271-283.
Romero, et al., “Current status of meningococcal group B vaccine cadidates: capsular or noncapsular?,”Clin. Microbiol. Rev., 1994,7(4), 559-575.
Rosenfeld, et al., “Adenovirus-mediated transfer of a recombinant α1-antitrypsin gene to the lung epithelium in vivo,”Science, 1991,252, 431-434.
Schuchat et al., “Bacterial Meningitis in the U. S. in 1995,”N. Engl. J. Med., 1997,337(14), 970-976.
Wedege, E., et al., “Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting,”Infection and Immunity, Feb. 1986,51(2), 571-578.
Ala'Aldeen, et al., “The meningococcal transferrin-binding proteins 1 and 2 are both surface exposed and generate bactericidal antibodies capable of killing homologous and heterologous strains,”Vaccine, 1996,14(1), 49-53.
Altschul, et al. “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,”Nucl. Acids Res., 1997,25, 2289-3402.
Berkner, “Development of adenovirus vectors for the expression of heterologous genes,”Biotechniques, 1988,6, 616-629.
Connelly, et al., “In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice,”Human Gene Therapy, 1995,6, 185-193.
Costantino, et al., “Development and phase I clinical testing of a conjugate vaccine against meningococcus A and C,”Vaccine, 1992,10, 691-698.
Donnelly, et al., “DNA vaccines,”Annu. Rev. Immunol., 1997,15, 617-648.
Esposti et al., “Critical evaluation of the hydropathy of membrane proteins,”Eur. J. Biochem., 1990,190, 207-219.
Gao, et al., “Identification and characterization of T helper epitopes in the nucleoprotein of influenza a virus,”J. Immunol., 1989,143, 3007-3014.
Jolly, “Viral vector systems for gene therapy,”Cancer Gene Therapy, 1994,1, 51-64.
Kimura, et al., “Retroviral delivery of DNA into the livers of transgenic mice bearing premalignant and malignant hepatocellular carcinomas,”Human Gene Therapy, 1994,5, 845-852.

Affiliated with

Also associated with

Rating

Neisserial antigens does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Neisserial antigens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neisserial antigens will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3374610